Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease

Clinical Cardiology

Volumn 23, Issue SUPPL. 6, 2000, Pages

  Montalescot, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Acute coronary syndromes; Antiplatelet agents; Clinical trials; Myocardial infarction; Peripheral artery disease; Stroke; Vascular disease

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TICLOPIDINE; TIROFIBAN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; SECONDARY PREVENTION; SURVIVAL RATE; TREATMENT FAILURE; UNSTABLE ANGINA PECTORIS;

EID: 0033664697     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960231106     Document Type: Review

References (36)

1. Risk of recurrent stroke, myocardial infarction and epilepsy during long-term follow-up after stroke
2. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study
3. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
4. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
5. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial
6. Abciximab associated with primary angioplasty and stenting in acute myocardial infarction: The ADMIRAL Study, 30-day final results
7. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
8. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
9. Pretreatment with ticlopidine prior to stenting is associated with a substantial decrease in complications: Data from the EPISTENT trial
10. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome. Results of the TIMI 12 trial
11. Oral platelet glycoprotein IIb/IIIa receptor blockers
12. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
13. Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study
14. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study
15. Clopidogrel, a novel antiplatelet and antithrombotic agent
16. Benefit of clopidogrel in patients with coronary disease
17. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates
18. Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event
19. European Stroke Prevention Study 2. Dipyridamole and acetylsali-cylic acid in the secondary prevention of stroke
20. Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group
21. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
22. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study
23. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation
24. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS)
25. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting
26. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
27. Antiplatelet effect of ticlopidine after coronary stenting
28. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
29. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
30. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
31. Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting
32. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The CLASSICS Study
33. Clopidogrel versus ticlopidine after intracoronary stent placement
34. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study